XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Combined Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Total ImmunityBio Stockholders' (Deficit) Equity
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Noncontrolling Interests
Beginning Balance at Dec. 31, 2018 $ 81,943 $ 94,261 $ 35 $ 1,326,760 $ (1,232,320) $ (214) $ (12,318)
Beginning Balance, Shares at Dec. 31, 2018     348,677,955        
Issuance of common stock for equity investment 30,000 30,000 $ 0 30,000 0 0 0
Issuance of common stock for equity investment, Shares     2,047,500        
Stock-based compensation expense 3,421 3,421 $ 0 3,421 0 0 0
Exercise of stock options 4,086 4,086 $ 0 4,086 0 0 0
Exercise of stock options, Shares     1,995,120        
Exercise of warrants 41,864 41,864 $ 2 41,862 0 0 0
Exercise of warrants, Shares     19,664,050        
Vesting of restricted stock units (RSUs) 0 0 $ 0 0 0 0 0
Vesting of restricted stock units (RSUs), Shares     395,051        
Net share settlement for restricted stock unit vesting and option/warrant exercises (127) (127) $ 0 (127) 0 0 0
Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares     (124,345)        
Repurchase of common stock $ (2,501) (2,501) $ 0 0 (2,501) 0 0
Repurchase of common stock, Shares (473,586)   (678,336)        
Cumulative effect of the adoption of the new standard | Accounting Standards Update 2014-09 $ (682) (682) $ 0 0 (682) 0 0
Deconsolidation of Precision Biologics 18,353 0 0 0 0 0 18,353
Other comprehensive income 127 127 0 0 0 127 0
Net loss (160,158) (157,777) 0 0 (157,777) 0 (2,381)
Ending Balance at Dec. 31, 2019 $ 16,326 12,672 $ 37 1,406,002 (1,393,280) (87) 3,654
Ending Balance, Shares at Dec. 31, 2019 371,976,995   371,976,995        
Issuance of common stock, net $ 86,302 86,302 $ 1 86,301 0 0 0
Issuance of common stock, net, Shares     8,521,500        
Stock-based compensation expense 2,187 2,187 $ 0 2,187 0 0 0
Exercise of stock options 1,176 1,176 $ 0 1,176 0 0 0
Exercise of stock options, Shares     1,272,273        
Vesting of restricted stock units (RSUs) 0 0 $ 0 0 0 0 0
Vesting of restricted stock units (RSUs), Shares     648,336        
Net share settlement for restricted stock unit vesting and option/warrant exercises $ (503) (503) $ 0 (503) 0 0 0
Net share settlement for restricted stock unit vesting and option/warrant exercises, Shares     (175,962)        
Repurchase of common stock, Shares 0            
Other comprehensive income $ 209 209 $ 0 0 0 209 0
Net loss (224,187) (221,851) 0 0 (221,851) 0 (2,336)
Ending Balance at Dec. 31, 2020 $ (118,490) $ (119,808) $ 38 $ 1,495,163 $ (1,615,131) $ 122 $ 1,318
Ending Balance, Shares at Dec. 31, 2020 382,243,142   382,243,142